Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1 Myeloma Cells and Release Type-1 Cytokines.

Multiple myeloma (MM) remains incurable despite advances in chemotherapy, targeted therapies, and immunotherapy. Bispecific antibody (BiAb)-armed activated T cells (BATs) have been developed for targeting and treatment of solid and hematologic malignancies. BATs are serial killers of tumor cells, secrete Th cytokines, and induce adaptive cellular and humoral immune responses in patients (pts).